Ac-225-FPI-2059
225Ac-FPI-2059 (225Ac-3BP-227, 225Ac-IPN-01087) is the 225Ac-labeled analogue of 177Lu-IPN-1087, a [...]
Bi-213-DOTATOC
213Bi-DOTATOC is one alpha-labeled analogue of 90Y- and 177Lu-DOTATOC. This [...]
At-211-BC8-B10
211At-BC8-B10 is a radioimmunoconjugate containing the murine IgG1 anti-CD45 monoclonal [...]
Ac-225-DOTA-SP
225Ac-DOTA-SP (225Ac-Substance-P) is developed as local treatment for glioblastoma and [...]
Ra-223-Radium Dichloride
223Ra-Radium Dichloride (223Ra-Xofigo® previously known as 223Ra-Alpharadin), is a 223Ra [...]
Pb-212-DOTAMTATE
212Pb-DOTAMTATE (212Pb-AlphaMedix™) is a somatostatin analogue labeled with Lead-212 [...]
At-211-MX35-F(ab’)-2
211At-MX35-F(ab’)2 is a radiolabeled antibody fragment developed and characterized [...]
At-211-81C6 mAb (Neuradiab)
211At-81C6-mAb (anti tenascin, human/mouse chimeric antibody) is a radiotherapeutic based [...]
Ac-225-PSMA-617
225Ac-PSMA-617 is the next generation of prostate cancer treatment following [...]
Ac-225-Lintuzumab (Ac-225 Actimab-A™)
225Ac-Lintuzumab (225Ac-Actimab-A™, 225Ac-DOTA-huM195) is the new name of the lead [...]